The global market for Metastatic Melanoma Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Metastatic Melanoma Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metastatic Melanoma Drug.

The Metastatic Melanoma Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Metastatic Melanoma Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Metastatic Melanoma Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Metastatic Melanoma Drug Market Report

Report Metric	Details
Report Name	Metastatic Melanoma Drug Market
CAGR	5%
Segment by Type	AGI-134 ALT-801 ALT-803 AMG-232 Others
Segment by Application	Hospital Clinic Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Morphotek, Inc., NewLink Genetics Corporation, Novartis AG, Omeros Corporation, Oncolytics Biotech Inc., OncoSec Medical Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Pharmis Biofarmaceutica, Lda., Philogen S.p.A., Plexxikon Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Metastatic Melanoma Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Metastatic Melanoma Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Metastatic Melanoma Drug Market report?

Ans: The main players in the Metastatic Melanoma Drug Market are Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Morphotek, Inc., NewLink Genetics Corporation, Novartis AG, Omeros Corporation, Oncolytics Biotech Inc., OncoSec Medical Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Pharmis Biofarmaceutica, Lda., Philogen S.p.A., Plexxikon Inc.

What are the Application segmentation covered in the Metastatic Melanoma Drug Market report?

Ans: The Applications covered in the Metastatic Melanoma Drug Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Metastatic Melanoma Drug Market report?

Ans: The Types covered in the Metastatic Melanoma Drug Market report are AGI-134, ALT-801, ALT-803, AMG-232, Others

1 Metastatic Melanoma Drug Market Overview

1.1 Product Definition

1.2 Metastatic Melanoma Drug by Type

1.2.1 Global Metastatic Melanoma Drug Market Value Comparison by Type (2024 VS 2031)

1.2.2 AGI-134

1.2.3 ALT-801

1.2.4 ALT-803

1.2.5 AMG-232

1.2.6 Others

1.3 Metastatic Melanoma Drug by Application

1.3.1 Global Metastatic Melanoma Drug Market Value by Application (2024 VS 2031)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Global Metastatic Melanoma Drug Market Size Estimates and Forecasts

1.4.1 Global Metastatic Melanoma Drug Revenue 2020-2031

1.4.2 Global Metastatic Melanoma Drug Sales 2020-2031

1.4.3 Global Metastatic Melanoma Drug Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Metastatic Melanoma Drug Market Competition by Manufacturers

2.1 Global Metastatic Melanoma Drug Sales Market Share by Manufacturers (2020-2025)

2.2 Global Metastatic Melanoma Drug Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Metastatic Melanoma Drug Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Metastatic Melanoma Drug, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Metastatic Melanoma Drug, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Metastatic Melanoma Drug, Product Type & Application

2.7 Global Key Manufacturers of Metastatic Melanoma Drug, Date of Enter into This Industry

2.8 Global Metastatic Melanoma Drug Market Competitive Situation and Trends

2.8.1 Global Metastatic Melanoma Drug Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Metastatic Melanoma Drug Players Market Share by Revenue

2.8.3 Global Metastatic Melanoma Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Metastatic Melanoma Drug Market Scenario by Region

3.1 Global Metastatic Melanoma Drug Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Metastatic Melanoma Drug Sales by Region: 2020-2031

3.2.1 Global Metastatic Melanoma Drug Sales by Region: 2020-2025

3.2.2 Global Metastatic Melanoma Drug Sales by Region: 2026-2031

3.3 Global Metastatic Melanoma Drug Revenue by Region: 2020-2031

3.3.1 Global Metastatic Melanoma Drug Revenue by Region: 2020-2025

3.3.2 Global Metastatic Melanoma Drug Revenue by Region: 2026-2031

3.4 North America Metastatic Melanoma Drug Market Facts & Figures by Country

3.4.1 North America Metastatic Melanoma Drug Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Metastatic Melanoma Drug Sales by Country (2020-2031)

3.4.3 North America Metastatic Melanoma Drug Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Metastatic Melanoma Drug Market Facts & Figures by Country

3.5.1 Europe Metastatic Melanoma Drug Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Metastatic Melanoma Drug Sales by Country (2020-2031)

3.5.3 Europe Metastatic Melanoma Drug Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Metastatic Melanoma Drug Market Facts & Figures by Region

3.6.1 Asia Pacific Metastatic Melanoma Drug Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Metastatic Melanoma Drug Sales by Region (2020-2031)

3.6.3 Asia Pacific Metastatic Melanoma Drug Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Metastatic Melanoma Drug Market Facts & Figures by Country

3.7.1 Latin America Metastatic Melanoma Drug Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Metastatic Melanoma Drug Sales by Country (2020-2031)

3.7.3 Latin America Metastatic Melanoma Drug Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Metastatic Melanoma Drug Market Facts & Figures by Country

3.8.1 Middle East and Africa Metastatic Melanoma Drug Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Metastatic Melanoma Drug Sales by Country (2020-2031)

3.8.3 Middle East and Africa Metastatic Melanoma Drug Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Metastatic Melanoma Drug Sales by Type (2020-2031)

4.1.1 Global Metastatic Melanoma Drug Sales by Type (2020-2025)

4.1.2 Global Metastatic Melanoma Drug Sales by Type (2026-2031)

4.1.3 Global Metastatic Melanoma Drug Sales Market Share by Type (2020-2031)

4.2 Global Metastatic Melanoma Drug Revenue by Type (2020-2031)

4.2.1 Global Metastatic Melanoma Drug Revenue by Type (2020-2025)

4.2.2 Global Metastatic Melanoma Drug Revenue by Type (2026-2031)

4.2.3 Global Metastatic Melanoma Drug Revenue Market Share by Type (2020-2031)

4.3 Global Metastatic Melanoma Drug Price by Type (2020-2031)

5 Segment by Application

5.1 Global Metastatic Melanoma Drug Sales by Application (2020-2031)

5.1.1 Global Metastatic Melanoma Drug Sales by Application (2020-2025)

5.1.2 Global Metastatic Melanoma Drug Sales by Application (2026-2031)

5.1.3 Global Metastatic Melanoma Drug Sales Market Share by Application (2020-2031)

5.2 Global Metastatic Melanoma Drug Revenue by Application (2020-2031)

5.2.1 Global Metastatic Melanoma Drug Revenue by Application (2020-2025)

5.2.2 Global Metastatic Melanoma Drug Revenue by Application (2026-2031)

5.2.3 Global Metastatic Melanoma Drug Revenue Market Share by Application (2020-2031)

5.3 Global Metastatic Melanoma Drug Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Merck & Co., Inc.

6.1.1 Merck & Co., Inc. Company Information

6.1.2 Merck & Co., Inc. Description and Business Overview

6.1.3 Merck & Co., Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Merck & Co., Inc. Metastatic Melanoma Drug Product Portfolio

6.1.5 Merck & Co., Inc. Recent Developments/Updates

6.2 Merck KGaA

6.2.1 Merck KGaA Company Information

6.2.2 Merck KGaA Description and Business Overview

6.2.3 Merck KGaA Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Merck KGaA Metastatic Melanoma Drug Product Portfolio

6.2.5 Merck KGaA Recent Developments/Updates

6.3 Millennium Pharmaceuticals, Inc.

6.3.1 Millennium Pharmaceuticals, Inc. Company Information

6.3.2 Millennium Pharmaceuticals, Inc. Description and Business Overview

6.3.3 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product Portfolio

6.3.5 Millennium Pharmaceuticals, Inc. Recent Developments/Updates

6.4 Morphotek, Inc.

6.4.1 Morphotek, Inc. Company Information

6.4.2 Morphotek, Inc. Description and Business Overview

6.4.3 Morphotek, Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Morphotek, Inc. Metastatic Melanoma Drug Product Portfolio

6.4.5 Morphotek, Inc. Recent Developments/Updates

6.5 NewLink Genetics Corporation

6.5.1 NewLink Genetics Corporation Company Information

6.5.2 NewLink Genetics Corporation Description and Business Overview

6.5.3 NewLink Genetics Corporation Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2020-2025)

6.5.4 NewLink Genetics Corporation Metastatic Melanoma Drug Product Portfolio

6.5.5 NewLink Genetics Corporation Recent Developments/Updates

6.6 Novartis AG

6.6.1 Novartis AG Company Information

6.6.2 Novartis AG Description and Business Overview

6.6.3 Novartis AG Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Novartis AG Metastatic Melanoma Drug Product Portfolio

6.6.5 Novartis AG Recent Developments/Updates

6.7 Omeros Corporation

6.7.1 Omeros Corporation Company Information

6.7.2 Omeros Corporation Description and Business Overview

6.7.3 Omeros Corporation Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Omeros Corporation Metastatic Melanoma Drug Product Portfolio

6.7.5 Omeros Corporation Recent Developments/Updates

6.8 Oncolytics Biotech Inc.

6.8.1 Oncolytics Biotech Inc. Company Information

6.8.2 Oncolytics Biotech Inc. Description and Business Overview

6.8.3 Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Oncolytics Biotech Inc. Metastatic Melanoma Drug Product Portfolio

6.8.5 Oncolytics Biotech Inc. Recent Developments/Updates

6.9 OncoSec Medical Inc.

6.9.1 OncoSec Medical Inc. Company Information

6.9.2 OncoSec Medical Inc. Description and Business Overview

6.9.3 OncoSec Medical Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2020-2025)

6.9.4 OncoSec Medical Inc. Metastatic Melanoma Drug Product Portfolio

6.9.5 OncoSec Medical Inc. Recent Developments/Updates

6.10 Ono Pharmaceutical Co., Ltd.

6.10.1 Ono Pharmaceutical Co., Ltd. Company Information

6.10.2 Ono Pharmaceutical Co., Ltd. Description and Business Overview

6.10.3 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product Portfolio

6.10.5 Ono Pharmaceutical Co., Ltd. Recent Developments/Updates

6.11 Pfizer Inc.

6.11.1 Pfizer Inc. Company Information

6.11.2 Pfizer Inc. Description and Business Overview

6.11.3 Pfizer Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Pfizer Inc. Metastatic Melanoma Drug Product Portfolio

6.11.5 Pfizer Inc. Recent Developments/Updates

6.12 Pharmis Biofarmaceutica, Lda.

6.12.1 Pharmis Biofarmaceutica, Lda. Company Information

6.12.2 Pharmis Biofarmaceutica, Lda. Description and Business Overview

6.12.3 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product Portfolio

6.12.5 Pharmis Biofarmaceutica, Lda. Recent Developments/Updates

6.13 Philogen S.p.A.

6.13.1 Philogen S.p.A. Company Information

6.13.2 Philogen S.p.A. Description and Business Overview

6.13.3 Philogen S.p.A. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2020-2025)

6.13.4 Philogen S.p.A. Metastatic Melanoma Drug Product Portfolio

6.13.5 Philogen S.p.A. Recent Developments/Updates

6.14 Plexxikon Inc.

6.14.1 Plexxikon Inc. Company Information

6.14.2 Plexxikon Inc. Description and Business Overview

6.14.3 Plexxikon Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2020-2025)

6.14.4 Plexxikon Inc. Metastatic Melanoma Drug Product Portfolio

6.14.5 Plexxikon Inc. Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Metastatic Melanoma Drug Industry Chain Analysis

7.2 Metastatic Melanoma Drug Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Metastatic Melanoma Drug Production Mode & Process Analysis

7.4 Metastatic Melanoma Drug Sales and Marketing

7.4.1 Metastatic Melanoma Drug Sales Channels

7.4.2 Metastatic Melanoma Drug Distributors

7.5 Metastatic Melanoma Drug Customer Analysis

8 Metastatic Melanoma Drug Market Dynamics

8.1 Metastatic Melanoma Drug Industry Trends

8.2 Metastatic Melanoma Drug Market Drivers

8.3 Metastatic Melanoma Drug Market Challenges

8.4 Metastatic Melanoma Drug Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Merck& Co. Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Morphotek

NewLink Genetics Corporation

Novartis

Omeros Corporation

Oncolytics Biotech Inc

OncoSec Medical Inc

Ono Pharmaceutical Co Ltd

Pfizer Inc

Pharmis Biofarmaceutica, Lda.

Philogen

Plexxikon

List of Tables

Table 1. Global Metastatic Melanoma Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Metastatic Melanoma Drug Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Metastatic Melanoma Drug Market Competitive Situation by Manufacturers in 2024

Table 4. Global Metastatic Melanoma Drug Sales (K Pcs) of Key Manufacturers (2020-2025)

Table 5. Global Metastatic Melanoma Drug Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Metastatic Melanoma Drug Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Metastatic Melanoma Drug Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Metastatic Melanoma Drug Average Price (USD/Pcs) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Metastatic Melanoma Drug, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Metastatic Melanoma Drug, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Metastatic Melanoma Drug, Product Type & Application

Table 12. Global Key Manufacturers of Metastatic Melanoma Drug, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Metastatic Melanoma Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metastatic Melanoma Drug as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Metastatic Melanoma Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Metastatic Melanoma Drug Sales by Region (2020-2025) & (K Pcs)

Table 18. Global Metastatic Melanoma Drug Sales Market Share by Region (2020-2025)

Table 19. Global Metastatic Melanoma Drug Sales by Region (2026-2031) & (K Pcs)

Table 20. Global Metastatic Melanoma Drug Sales Market Share by Region (2026-2031)

Table 21. Global Metastatic Melanoma Drug Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Metastatic Melanoma Drug Revenue Market Share by Region (2020-2025)

Table 23. Global Metastatic Melanoma Drug Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Metastatic Melanoma Drug Revenue Market Share by Region (2026-2031)

Table 25. North America Metastatic Melanoma Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Metastatic Melanoma Drug Sales by Country (2020-2025) & (K Pcs)

Table 27. North America Metastatic Melanoma Drug Sales by Country (2026-2031) & (K Pcs)

Table 28. North America Metastatic Melanoma Drug Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Metastatic Melanoma Drug Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Metastatic Melanoma Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Metastatic Melanoma Drug Sales by Country (2020-2025) & (K Pcs)

Table 32. Europe Metastatic Melanoma Drug Sales by Country (2026-2031) & (K Pcs)

Table 33. Europe Metastatic Melanoma Drug Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Metastatic Melanoma Drug Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Metastatic Melanoma Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Metastatic Melanoma Drug Sales by Region (2020-2025) & (K Pcs)

Table 37. Asia Pacific Metastatic Melanoma Drug Sales by Region (2026-2031) & (K Pcs)

Table 38. Asia Pacific Metastatic Melanoma Drug Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Metastatic Melanoma Drug Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Metastatic Melanoma Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Metastatic Melanoma Drug Sales by Country (2020-2025) & (K Pcs)

Table 42. Latin America Metastatic Melanoma Drug Sales by Country (2026-2031) & (K Pcs)

Table 43. Latin America Metastatic Melanoma Drug Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Metastatic Melanoma Drug Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Metastatic Melanoma Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Metastatic Melanoma Drug Sales by Country (2020-2025) & (K Pcs)

Table 47. Middle East and Africa Metastatic Melanoma Drug Sales by Country (2026-2031) & (K Pcs)

Table 48. Middle East and Africa Metastatic Melanoma Drug Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Metastatic Melanoma Drug Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Metastatic Melanoma Drug Sales (K Pcs) by Type (2020-2025)

Table 51. Global Metastatic Melanoma Drug Sales (K Pcs) by Type (2026-2031)

Table 52. Global Metastatic Melanoma Drug Sales Market Share by Type (2020-2025)

Table 53. Global Metastatic Melanoma Drug Sales Market Share by Type (2026-2031)

Table 54. Global Metastatic Melanoma Drug Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Metastatic Melanoma Drug Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Metastatic Melanoma Drug Revenue Market Share by Type (2020-2025)

Table 57. Global Metastatic Melanoma Drug Revenue Market Share by Type (2026-2031)

Table 58. Global Metastatic Melanoma Drug Price (USD/Pcs) by Type (2020-2025)

Table 59. Global Metastatic Melanoma Drug Price (USD/Pcs) by Type (2026-2031)

Table 60. Global Metastatic Melanoma Drug Sales (K Pcs) by Application (2020-2025)

Table 61. Global Metastatic Melanoma Drug Sales (K Pcs) by Application (2026-2031)

Table 62. Global Metastatic Melanoma Drug Sales Market Share by Application (2020-2025)

Table 63. Global Metastatic Melanoma Drug Sales Market Share by Application (2026-2031)

Table 64. Global Metastatic Melanoma Drug Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Metastatic Melanoma Drug Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Metastatic Melanoma Drug Revenue Market Share by Application (2020-2025)

Table 67. Global Metastatic Melanoma Drug Revenue Market Share by Application (2026-2031)

Table 68. Global Metastatic Melanoma Drug Price (USD/Pcs) by Application (2020-2025)

Table 69. Global Metastatic Melanoma Drug Price (USD/Pcs) by Application (2026-2031)

Table 70. Merck & Co., Inc. Company Information

Table 71. Merck & Co., Inc. Description and Business Overview

Table 72. Merck & Co., Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 73. Merck & Co., Inc. Metastatic Melanoma Drug Product

Table 74. Merck & Co., Inc. Recent Developments/Updates

Table 75. Merck KGaA Company Information

Table 76. Merck KGaA Description and Business Overview

Table 77. Merck KGaA Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 78. Merck KGaA Metastatic Melanoma Drug Product

Table 79. Merck KGaA Recent Developments/Updates

Table 80. Millennium Pharmaceuticals, Inc. Company Information

Table 81. Millennium Pharmaceuticals, Inc. Description and Business Overview

Table 82. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 83. Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product

Table 84. Millennium Pharmaceuticals, Inc. Recent Developments/Updates

Table 85. Morphotek, Inc. Company Information

Table 86. Morphotek, Inc. Description and Business Overview

Table 87. Morphotek, Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 88. Morphotek, Inc. Metastatic Melanoma Drug Product

Table 89. Morphotek, Inc. Recent Developments/Updates

Table 90. NewLink Genetics Corporation Company Information

Table 91. NewLink Genetics Corporation Description and Business Overview

Table 92. NewLink Genetics Corporation Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 93. NewLink Genetics Corporation Metastatic Melanoma Drug Product

Table 94. NewLink Genetics Corporation Recent Developments/Updates

Table 95. Novartis AG Company Information

Table 96. Novartis AG Description and Business Overview

Table 97. Novartis AG Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 98. Novartis AG Metastatic Melanoma Drug Product

Table 99. Novartis AG Recent Developments/Updates

Table 100. Omeros Corporation Company Information

Table 101. Omeros Corporation Description and Business Overview

Table 102. Omeros Corporation Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 103. Omeros Corporation Metastatic Melanoma Drug Product

Table 104. Omeros Corporation Recent Developments/Updates

Table 105. Oncolytics Biotech Inc. Company Information

Table 106. Oncolytics Biotech Inc. Description and Business Overview

Table 107. Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 108. Oncolytics Biotech Inc. Metastatic Melanoma Drug Product

Table 109. Oncolytics Biotech Inc. Recent Developments/Updates

Table 110. OncoSec Medical Inc. Company Information

Table 111. OncoSec Medical Inc. Description and Business Overview

Table 112. OncoSec Medical Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 113. OncoSec Medical Inc. Metastatic Melanoma Drug Product

Table 114. OncoSec Medical Inc. Recent Developments/Updates

Table 115. Ono Pharmaceutical Co., Ltd. Company Information

Table 116. Ono Pharmaceutical Co., Ltd. Description and Business Overview

Table 117. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 118. Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product

Table 119. Ono Pharmaceutical Co., Ltd. Recent Developments/Updates

Table 120. Pfizer Inc. Company Information

Table 121. Pfizer Inc. Description and Business Overview

Table 122. Pfizer Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 123. Pfizer Inc. Metastatic Melanoma Drug Product

Table 124. Pfizer Inc. Recent Developments/Updates

Table 125. Pharmis Biofarmaceutica, Lda. Company Information

Table 126. Pharmis Biofarmaceutica, Lda. Description and Business Overview

Table 127. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 128. Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product

Table 129. Pharmis Biofarmaceutica, Lda. Recent Developments/Updates

Table 130. Philogen S.p.A. Company Information

Table 131. Philogen S.p.A. Description and Business Overview

Table 132. Philogen S.p.A. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 133. Philogen S.p.A. Metastatic Melanoma Drug Product

Table 134. Philogen S.p.A. Recent Developments/Updates

Table 135. Plexxikon Inc. Company Information

Table 136. Plexxikon Inc. Description and Business Overview

Table 137. Plexxikon Inc. Metastatic Melanoma Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 138. Plexxikon Inc. Metastatic Melanoma Drug Product

Table 139. Plexxikon Inc. Recent Developments/Updates

Table 140. Key Raw Materials Lists

Table 141. Raw Materials Key Suppliers Lists

Table 142. Metastatic Melanoma Drug Distributors List

Table 143. Metastatic Melanoma Drug Customers List

Table 144. Metastatic Melanoma Drug Market Trends

Table 145. Metastatic Melanoma Drug Market Drivers

Table 146. Metastatic Melanoma Drug Market Challenges

Table 147. Metastatic Melanoma Drug Market Restraints

Table 148. Research Programs/Design for This Report

Table 149. Key Data Information from Secondary Sources

Table 150. Key Data Information from Primary Sources

Table 151. Authors List of This Report

List of Figures

Figure 1. Product Picture of Metastatic Melanoma Drug

Figure 2. Global Metastatic Melanoma Drug Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Metastatic Melanoma Drug Market Share by Type: 2024 & 2031

Figure 4. AGI-134 Product Picture

Figure 5. ALT-801 Product Picture

Figure 6. ALT-803 Product Picture

Figure 7. AMG-232 Product Picture

Figure 8. Others Product Picture

Figure 9. Global Metastatic Melanoma Drug Market Value by Application (2020-2031) & (US$ Million)

Figure 10. Global Metastatic Melanoma Drug Market Share by Application: 2024 & 2031

Figure 11. Hospital

Figure 12. Clinic

Figure 13. Others

Figure 14. Global Metastatic Melanoma Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Metastatic Melanoma Drug Market Size (2020-2031) & (US$ Million)

Figure 16. Global Metastatic Melanoma Drug Sales (2020-2031) & (K Pcs)

Figure 17. Global Metastatic Melanoma Drug Average Price (USD/Pcs) & (2020-2031)

Figure 18. Metastatic Melanoma Drug Report Years Considered

Figure 19. Metastatic Melanoma Drug Sales Share by Manufacturers in 2024

Figure 20. Global Metastatic Melanoma Drug Revenue Share by Manufacturers in 2024

Figure 21. Global 5 and 10 Largest Metastatic Melanoma Drug Players: Market Share by Revenue in Metastatic Melanoma Drug in 2024

Figure 22. Metastatic Melanoma Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 23. Global Metastatic Melanoma Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 24. North America Metastatic Melanoma Drug Sales Market Share by Country (2020-2031)

Figure 25. North America Metastatic Melanoma Drug Revenue Market Share by Country (2020-2031)

Figure 26. U.S. Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. Canada Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. Europe Metastatic Melanoma Drug Sales Market Share by Country (2020-2031)

Figure 29. Europe Metastatic Melanoma Drug Revenue Market Share by Country (2020-2031)

Figure 30. Germany Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. France Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. U.K. Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Italy Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Russia Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Asia Pacific Metastatic Melanoma Drug Sales Market Share by Region (2020-2031)

Figure 36. Asia Pacific Metastatic Melanoma Drug Revenue Market Share by Region (2020-2031)

Figure 37. China Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Japan Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. South Korea Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. India Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Australia Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Taiwan Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Indonesia Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Thailand Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Malaysia Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Philippines Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Latin America Metastatic Melanoma Drug Sales Market Share by Country (2020-2031)

Figure 48. Latin America Metastatic Melanoma Drug Revenue Market Share by Country (2020-2031)

Figure 49. Mexico Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Brazil Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Argentina Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Middle East and Africa Metastatic Melanoma Drug Sales Market Share by Country (2020-2031)

Figure 53. Middle East and Africa Metastatic Melanoma Drug Revenue Market Share by Country (2020-2031)

Figure 54. Turkey Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Saudi Arabia Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 56. U.A.E Metastatic Melanoma Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 57. Global Sales Market Share of Metastatic Melanoma Drug by Type (2020-2031)

Figure 58. Global Revenue Market Share of Metastatic Melanoma Drug by Type (2020-2031)

Figure 59. Global Metastatic Melanoma Drug Price (USD/Pcs) by Type (2020-2031)

Figure 60. Global Sales Market Share of Metastatic Melanoma Drug by Application (2020-2031)

Figure 61. Global Revenue Market Share of Metastatic Melanoma Drug by Application (2020-2031)

Figure 62. Global Metastatic Melanoma Drug Price (USD/Pcs) by Application (2020-2031)

Figure 63. Metastatic Melanoma Drug Value Chain

Figure 64. Channels of Distribution (Direct Vs Distribution)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Precision Cancer Imaging System Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-23Z10214

Thu Feb 20 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Cryosurgical Equipment for Cancer Treatment Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-39B12765

Thu Feb 20 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Brachytherapy Accessories Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-24Q18678

Tue Feb 18 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Gynecological Cancer Diagnostics Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-30P10282

Mon Feb 17 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions